Vanguard Asset Management
SPRY icon

Vanguard Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Vanguard Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324K Hold
40,388
– – ﹤0.01% 2320
2026
Q1 		$324K Buy
+40,388
New +$387K ﹤0.01% 2275

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Asset Management's SPRY Position: Q2 2026 in Review

Vanguard Asset Management held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 40,388 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #2320.

Vanguard Asset Management first reported a position in SPRY in Q1 2026 and has held it in 2 quarters since. The position peaked at $324K in Q1 2026. 192 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Vanguard Asset Management held 40,388 shares of ARS Pharmaceuticals worth $324K as of Q2 2026.
  • Vanguard Asset Management left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2320 holding.
  • Vanguard Asset Management first reported a position in ARS Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Asset Management's ARS Pharmaceuticals position peaked at $324K in Q1 2026.
  • 192 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.